We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cara Therapeutics Inc | NASDAQ:CARA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.006 | 0.78% | 0.7782 | 0.62 | 0.785 | 0.7969 | 0.7571 | 0.7969 | 159,125 | 05:00:13 |
From May 2021 to May 2024
By Stephen Nakrosis
Cara Therapeutics and Vifor Pharma on Monday said the U.S. Food and Drug Administration approved the Korsuva injection to treat pruritus in hemodialysis patients.
The companies said the Korsuva, or difelikefalin, injection was approved to treat moderate-to-severe pruritus in hemodialysis patients.
The companies said the Korsuva injection is the first and only therapy approved by the FDA to treat pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.
The companies said the promotional launch of Korsuva injection in the U.S. is expected in the first quarter of next year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 23, 2021 16:46 ET (20:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Cara Therapeutics Chart |
1 Month Cara Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
